Satyendra Pal Singh
About Satyendra Pal Singh
Data last updated:
Satyendra Pal Singh is a Director at Lumetiq Technologies Private Limited (since 2018) and Director at Impileo Healthcare Limited (since 2025). The companies operate in Consumer Electronics & Durables. The largest current company by reported revenue is Lumetiq Technologies Private Limited at ₹2.31 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Lumetiq Technologies Private Limited U31900PB2018PTC048313 | Director | 05 Sep 2018 | 2018 | ₹2.31 Cr (FY 2025) | Active |
| Impileo Healthcare Limited U46497HR2025PLC131565 | Director | 02 May 2025 | 2025 | Active |
Board colleagues of Satyendra Pal Singh
| Name | DIN | Company | Designation |
|---|---|---|---|
| Ritu Singh | 08215542 | Lumetiq Technologies Private Limited , Impileo Healthcare Limited | Director |
| Ashu Singla | 09212075 | Impileo Healthcare Limited | Director |
| Rajni Singla | 11060603 | Impileo Healthcare Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Satyendra Pal Singh
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Satyendra Pal Singh
Satyendra Pal Singh currently holds 2 directorships: Lumetiq Technologies Private Limited (Director, since 05 Sep 2018, revenue ₹2.31 Cr (FY 2025)); Impileo Healthcare Limited (Director, since 02 May 2025).
Satyendra Pal Singh was first appointed on 05 Sep 2018 as Director at Lumetiq Technologies Private Limited. The most recent appointment on record is 02 May 2025 at Impileo Healthcare Limited.
The current boards of Satyendra Pal Singh's companies include Ritu Singh (Lumetiq Technologies Private Limited), Ashu Singla (Impileo Healthcare Limited), Rajni Singla (Impileo Healthcare Limited).